Market Overview

KYTHERA Biopharmaceuticals Presents Positive MRI Results from Phase IIb Study of ATX-101 in Reduction of Double Chin


KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today presented positive
results that found MRI measurements of patients treated with ATX-101
demonstrated a statistically significant reduction in submental fat
(SMF), commonly known as double chin, during an oral session at The
Aesthetic Meeting 2013, organized by the American Society for Aesthetic
Plastic Surgery (ASAPS), April 11-16, New York, NY. MRI assessments were
performed in the study as a quantifiable and objective measure of
submental fat volume and thickness. The same study also demonstrated
positive results based on validated clinician- and patient-reported
outcome measures. The results are from a Phase IIb, multicenter,
randomized, double-blind, placebo-controlled study (ATX-101-09-15) to
evaluate the safety and efficacy of ATX-101, a potential first-in-class,
non-surgical, injectable

See full press release

Posted-In: Earnings News Guidance Contracts Asset Sales M&A Global


Related Articles (KYTH)

View Comments and Join the Discussion!

Partner Center